{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+controlled&page=113",
    "query": {
      "intervention": "Placebo controlled",
      "page": 113
    },
    "page_size": 10
  },
  "pagination": {
    "page": 113,
    "page_size": 10,
    "total_count": 33046,
    "total_pages": 3305,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+controlled&page=114&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+controlled&page=112&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T03:48:28.003Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04483973",
      "title": "SPI-1005 Treatment in Severe COVID-19 Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "Coronavirus",
        "Coronavirus Infection",
        "Corona Virus Infection"
      ],
      "interventions": [
        {
          "name": "Ebselen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sound Pharmaceuticals, Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-08-27",
      "completion_date": "2023-06-06",
      "has_results": true,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-11-21T03:48:28.003Z",
      "location_count": 7,
      "location_summary": "New Haven, Connecticut • Boise, Idaho • Kansas City, Kansas + 4 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04483973"
    },
    {
      "nct_id": "NCT03304054",
      "title": "Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myasthenia Gravis, Generalized"
      ],
      "interventions": [
        {
          "name": "Amifampridine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Catalyst Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2018-04-18",
      "completion_date": "2020-03-15",
      "has_results": true,
      "last_update_posted_date": "2024-03-12",
      "last_synced_at": "2026-11-21T03:48:28.003Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03304054"
    },
    {
      "nct_id": "NCT02563522",
      "title": "Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Foot Ulcer, Diabetic"
      ],
      "interventions": [
        {
          "name": "Engensis (VM202)",
          "type": "GENETIC"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Helixmith Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 44,
      "start_date": "2017-06-27",
      "completion_date": "2019-09-24",
      "has_results": true,
      "last_update_posted_date": "2025-10-09",
      "last_synced_at": "2026-11-21T03:48:28.003Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Carmichael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02563522"
    },
    {
      "nct_id": "NCT03893422",
      "title": "Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "WB-010",
          "type": "OTHER"
        },
        {
          "name": "WB-011",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Pendulum Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 76,
      "start_date": "2017-10-22",
      "completion_date": "2018-09-14",
      "has_results": false,
      "last_update_posted_date": "2020-02-27",
      "last_synced_at": "2026-11-21T03:48:28.003Z",
      "location_count": 5,
      "location_summary": "Torrance, California • Tustin, California • Youngstown, Ohio + 2 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Youngstown",
          "state": "Ohio"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03893422"
    },
    {
      "nct_id": "NCT04821622",
      "title": "Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "talazoparib plus enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo plus enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 599,
      "start_date": "2021-05-12",
      "completion_date": "2027-08-28",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-21T03:48:28.003Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04821622"
    },
    {
      "nct_id": "NCT02178566",
      "title": "Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Inhaled Treprostinil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inova Health Care Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2015-08",
      "completion_date": "2019-01",
      "has_results": true,
      "last_update_posted_date": "2022-04-12",
      "last_synced_at": "2026-11-21T03:48:28.003Z",
      "location_count": 1,
      "location_summary": "Falls Church, Virginia",
      "locations": [
        {
          "city": "Falls Church",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02178566"
    },
    {
      "nct_id": "NCT05123222",
      "title": "Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Zika Virus"
      ],
      "interventions": [
        {
          "name": "ZIKV-SJRP/2016-184 Strain",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Experimental: ZIKV-Nicaragua/2016 Strain",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 56,
      "start_date": "2022-02-16",
      "completion_date": "2024-09-03",
      "has_results": true,
      "last_update_posted_date": "2025-04-11",
      "last_synced_at": "2026-11-21T03:48:28.003Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05123222"
    },
    {
      "nct_id": "NCT05217927",
      "title": "Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Rimegepant 75mg daily dosing",
          "type": "DRUG"
        },
        {
          "name": "Rimegepant 75mg every other day dosing",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator dosing",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1415,
      "start_date": "2022-03-04",
      "completion_date": "2024-12-11",
      "has_results": true,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-11-21T03:48:28.003Z",
      "location_count": 30,
      "location_summary": "Tempe, Arizona • Colton, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05217927"
    },
    {
      "nct_id": "NCT02916927",
      "title": "Intravenous Sub-dissociative Dose Ketamine Injection Versus Infusion for Analgesia in the Emergency Department",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Ketamine IV Infusion",
          "type": "DRUG"
        },
        {
          "name": "Ketamine IV push",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alameda Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2016-09",
      "completion_date": "2017-04",
      "has_results": true,
      "last_update_posted_date": "2020-04-17",
      "last_synced_at": "2026-11-21T03:48:28.003Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02916927"
    },
    {
      "nct_id": "NCT00630370",
      "title": "A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Prandial Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "20 mg ATI 7505",
          "type": "DRUG"
        },
        {
          "name": "40 mg ATI 7505",
          "type": "DRUG"
        },
        {
          "name": "80 mg ATI 7505",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Procter and Gamble",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 6,
      "start_date": "2008-02",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2009-06-17",
      "last_synced_at": "2026-11-21T03:48:28.003Z",
      "location_count": 44,
      "location_summary": "Chino, California • Fresno, California • Los Angeles, California + 37 more",
      "locations": [
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00630370"
    }
  ]
}